We validated our analyses in an independent cohort comprehending 105 consecutive patients diagnosed with AML and treated in the Netherlands (validation cohort), which was compared to healthy mobilized CD34+ cells (n = 10) (supplementary Fig. 1b). This evidence concerns the gene CD34 and acute myeloid leukemia.